The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like What is dihexa, its mechanism of action via the HGF c Met pathway, and its safety and clinical use? RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica DIHEXA PEPTIDE 10MG VIAL UMBRELLA Labs CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA FDA Announces Change in Status of 12 Peptides SSRP Institute